Martin I, Smith T, Wendt D. Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products.
Trends Biotechnol 2009;
27:495-502. [PMID:
19651453 DOI:
10.1016/j.tibtech.2009.06.002]
[Citation(s) in RCA: 108] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Revised: 06/05/2009] [Accepted: 06/05/2009] [Indexed: 11/25/2022]
Abstract
Despite the compelling clinical need to regenerate damaged tissues/organs, impressive advances in the field of tissue engineering have yet to result in viable engineered tissue products with widespread therapeutic adoption. Although bioreactor systems have been proposed as a key factor in the manufacture of standardized and cost-effective engineered products, this concept appears slow to be embraced and implemented. Here we address scientific, regulatory and commercial challenges intrinsic to the bioreactor-based translation of tissue engineering models into clinical products, proposing a roadmap for the implementation of a new paradigm. The roadmap highlights that bioreactors must be implemented throughout product development, allowing scientific, medical, industrial and regulatory parties to address basic research questions, conduct sound pre-clinical studies and ultimately facilitating effective commercialization of engineered clinical products.
Collapse